Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150797 · ClinicalTrials.gov registry record · Phase 2
Melatonin for Adolescent Migraine Prevention Study
A Phase 2 study, sponsored by Amy Gelfand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT03150797 is a Phase 2 study that was terminated before completion, run by Amy Gelfand. The registered enrollment target is 72 participants.
The verdict
NCT03150797, a Phase 2 study, was terminated before completion, sponsored by Amy Gelfand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each participant will be 4 months.
Interventions
- DRUG Melatonin
- DRUG Placebo oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03150797
The ClinicalTrials.gov registry entry for NCT03150797 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amy Gelfand, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melatonin is the first listed.
NCT03150797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03150797 about?
NCT03150797 is a clinical study titled "Melatonin for Adolescent Migraine Prevention Study". This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each...
What is the current status of trial NCT03150797?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2017-08-02. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT03150797?
The interventions under investigation include: Melatonin (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03150797?
This trial is sponsored by Amy Gelfand, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.